Orthocell Ltd ( (AU:OCC) ) has issued an announcement.
Orthocell Limited is accelerating its global expansion following strong sales of Remplir™ in Australia, New Zealand, and Singapore. The company has submitted a 510(k) application to the U.S. FDA, aiming to enter the $1.6 billion U.S. nerve repair market, with approval anticipated by March or April 2025. This move is part of Orthocell’s broader strategy to enhance its market positioning and engage in partnering discussions in the U.S.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company specializing in products for repairing bone and soft tissue injuries. Their product portfolio includes the CelGro™ platform for tissue reconstruction, Striate+™ for dental applications, Remplir™ for peripheral nerve reconstruction, and SmrtGraft™ for tendon repair. The company is actively expanding its market presence globally, with a focus on the U.S. market.
YTD Price Performance: 4.06%
Average Trading Volume: 1,830,174
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$340.1M
See more data about OCC stock on TipRanks’ Stock Analysis page.